Metronomic Capecitabine in Patients With Hepatocellular Carcinoma Unresponsive to or Ineligible for Sorafenib Treatment: Report of Two Cases
Open Access
- 9 September 2013
- journal article
- Published by Briefland in Hepatitis Monthly
- Vol. 13 (9), e11721
- https://doi.org/10.5812/hepatmon.11721
Abstract
Introduction: Sorafenib, an oral multikinase inhibitor, is the only systemic agent proven to be effective in patients with hepatocellular carcinoma (HCC). There are no approved second line systemic therapies in patients who have had disease progression on or are not eligible to sorafenib. Case Presentation: We describe two cases of unresectable HCC that were treated with low, "metronomic" doses of capecitabine. In the first patient, capecitabine was used after sorafenib failure. In the second case, treatment with capecitabine was attempted since the patient was considered not eligible for sorafenib due to spontaneous hepatic bleeding of a large HCC lesion. Treatment was effective and well tolerated in both patients with long-lasting objective responses. Conclusions: Lacking established second-line therapy, metronomic capecitabine may be a valid alternative in the treatment of HCC patients who are judged not eligible for sorafenib or those having progression disease on sorafenib. Keywords: Hepatocellular Carcinoma; Capecitabine; SorafenibKeywords
This publication has 14 references indexed in Scilit:
- Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapiesJournal of Hepatology, 2012
- Targeted Therapies for Hepatocellular CarcinomaGastroenterology, 2011
- Durable Complete Response of Hepatocellular Carcinoma after Metronomic CapecitabineTumori Journal, 2010
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- Capecitabine-Induced Cardiotoxicity: Case Report and Review of the LiteratureCurrent Oncology, 2010
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialThe Lancet Oncology, 2008
- Five Years of Clinical Experience with Metronomic Chemotherapy: Achievements and PerspectivesOncology Research and Treatment, 2007
- Management of hepatocellular carcinomaJournal of Hepatology, 2005
- Capecitabine: A reviewClinical Therapeutics, 2005
- The anti-angiogenic basis of metronomic chemotherapyNature Reviews Cancer, 2004